Switch Seeks $2 Billion Funding at Nearly $50 Billion Valuation Ahead of Potential IPO 
Norway Offshore Oil Workers Reach Wage Deal, Averting Strike 
DOJ Seeks Dismissal of Fraud Charges Against Gautam Adani in U.S. Court 
TetherMax Rebranding Highlights Official Exchange Partnerships as Foundation of Trust 
Tesla Q2 Deliveries Lift Chinese Auto Suppliers as EV Demand Improves 
Kuaishou Stock Jumps as Kling AI Secures $2 Billion Funding Round 
Super Micro Employees Detained in Taiwan AI Server Export Investigation 
SoftBank’s LY Corp, Bain Raise Kakaku.com Bid to ¥670 Billion, Intensifying Takeover Battle 
Texas Man Charged After Fatal Tesla Full Self-Driving Crash in Katy 
easyJet Agrees in Principle to £5.23 Billion Castlelake Takeover Offer 
BHP Workers Approve New Labour Agreement at WA Iron Ore Operations 
Northern Star Appoints New CEO as Activist Elliott Pushes for Leadership Overhaul 
Foxconn Q2 Revenue Surges Nearly 40% on Strong AI Server Demand 
Anthropic Tightens AI Access Controls After Reports of China-Based Workarounds 
Meta CEO Zuckerberg Says AI Agent Development Has Slowed Despite Massive AI Investment 
AI Memory Chip Shortage Likely to Persist Despite Korea Investment Boom, Nomura Says 
The U.S. Federal Circuit Court of Appeals in Washington, D.C. reinstated a 2017 jury verdict ordering Teva Pharmaceutical Industries Ltd to pay $235.5 million to GlaxoSmithKline Plc for selling a generic version of a heart drug, covered by the latter's patent.
In a 2-1 decision, the appeals court found “substantial evidence” that Teva induced doctors to prescribe its generic tablets.
Israeli drugmaker Teva plans to appeal and introduce additional defenses that it neither infringed nor induced doctors to infringe Glaxo’s patent.
The case arose after Teva began selling a generic version of Coreg, which Glaxo had won U.S. approval for, in 2007.
Coreg treats hypertension, left ventricular dysfunction after a heart attack, and congestive heart failure.
In 2017, a Delaware jury ordered the to pay $234.1 million for lost profit plus $1.4 million in royalties.
US District Judge Leonard Stark overturned the verdict due to other factors that could have caused doctors to prescribe Coreg.
But Circuit Judge Pauline Newman said Teva's promotional materials, product catalogs, the FDA labels, press releases, and witness testimony supported allegations of “induced infringement.”
